(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
6 Novice Cameras for 2024: Ideal for New Picture takers- Significant Elements to Consider Prior to Applying for a Mastercard: 6 Vital Contemplations
- New science points to 4 distinct types of autism
- Native artists in Texas and Mexico shared their vision of the universe for 4,000 years, ancient murals suggest
- Canada Awards C$1.5 Billion Defense Contracts to L3Harris, Airbus
- Key Little Things That Advantage Old People
- Top notch Remote Earphones for Audiophiles
- AfD faction in western Germany ousts councilman for firebrand speech
- Watching ‘Home Alone’ with the kids this holiday season? Brace yourself for '6-7.'
